108919 Results

Show all   Save search   Copy query
Sort   by:  
 Page size 
MetabolomicsHistorical Biobanks in Breast Cancer Metabolomics - Challenges and Opportunities

BACKGROUND: Metabolomic characterization of tumours can potentially improve prediction of cancer prognosis and treatment response. Here, we describe efforts to validate previous metabolomic findings using a historical cohort of breast cancer patients and discuss challenges with u...

2022-01-24 | MTBLS1355 | MetaboLights
MetabolomicsMetabolomics revealed the influence of breast cancer on lymphatic endothelial cell metabolism, metabolic crosstalk, and lymphangiogenic signaling in co-culture

Breast cancer metastasis occurs via blood and lymphatic vessels. Breast cancer cells 'educate' lymphatic endothelial cells (LECs) to support tumor vascularization and growth. However, despite known metabolic alterations in breast cancer, it remains unclear how lymphatic endothelial cell metabolis...

2024-06-25 | MTBLS859 | MetaboLights
MetabolomicsNormalization strategies for lipidome data in cell line panels & Distinct lipidomic profiles in breast cancer cell lines relate to proliferation and EMT phenotypes

Sample collection can significantly affect measurements of relative lipid concentrations in cell line panels, hiding intrinsic biological properties of interest between cell lines. Most quality control steps in lipidomic data analysis focus on controlling technical variation. Correcting for the t...

2025-08-07 | MTBLS9493 | MetaboLights
MetabolomicsThioridazine induce phospholipid accumulation and necroptosis in breast cancer cells
An antipsychotic drug, Thioridazine has been shown to inhibit a broad spectrum of cancer cells. However, its molecular mechanism is still not well understood. In the present study, we have shown that thioridazine induces cytostatic effects in both parental and tamoxifen-resistant cancer cells throug...
2025-02-20 | MTBLS11870 | MetaboLights
MetabolomicsSerum metabolomic profiles identify ER-positive early breast cancer patients at increased risk of disease recurrence in a multicentre population

PURPOSE: Detecting signals of micrometastatic disease in early breast cancer (EBC) patients could improve risk stratification and allow better tailoring of adjuvant therapies. We have previously shown that postoperative serum metabolomic profiles are predictive of relapse in a si...

2017-03-02 | MTBLS424 | MetaboLights
MetabolomicsTargeting PI3K inhibitor resistance in breast cancer with metabolic drugs

Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2-) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly improves ...

2026-08-21 | MTBLS11671 | MetaboLights
MetabolomicsMulti-omics characterization of acquired Olaparib resistance in BRCA1 and BRCA2 mutant breast cancer cell lines
Poly (ADP-ribose) polymerase inhibitors (PARPi) are widely used as targeted therapies against breast cancers with BRCA mutations. However, the development of resistance to PARPi poses a significant challenge for long-term efficacy of these therapies, warranting further understanding of mechanisms of...
2026-05-11 | MTBLS12109 | MetaboLights
MetabolomicsVesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer

Selective autophagy of mitochondria is known to promote survival and progression of cancer cells in various malignancies, including triple-negative breast cancer (TNBC). Here, we investigate the essential metabolic adaptations that support mitochondrial quality control in cancer cells with the ai...

2025-09-30 | MTBLS13037 | MetaboLights
MetabolomicsOrganotypic microfluidic breast cancer model reveals starvation-induced spatial-temporal metabolic adaptations
BACKGROUND: Ductal carcinoma in situ (DCIS) is the earliest stage of breast cancer. During DCIS, tumor cells remain inside the mammary duct, growing under a microenvironment characterized by hypoxia, nutrient starvation, and waste product accumulation; this harsh microenvironment promotes genomic in...
2019-02-08 | MTBLS669 | MetaboLights
MetabolomicsTargeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in ARID1A-deficient triple negative breast cancer

Bone metastasis is a lethal consequence of breast cancer. AT-rich interaction domain 1A gene (ARID1A), a subunit of the switch/sucrose non-fermentable (SWI/SNF) complex, regulates immunosuppressive tumor microenvironment. ARID1A deficient triple negative breast cancer promotes bone metastasis.To ...

2026-03-24 | MTBLS12768 | MetaboLights
Sort   by:  
 Page size